Are you Dr. Silva?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 62 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3525 E Louise Dr
Ste 195
Meridian, ID 83642Phone+1 208-846-8335Fax+1 208-846-8335
Summary
- Dr. Arnold Silva, MD is a nephrologist in Meridian, Idaho. He is currently licensed to practice medicine in Idaho and Arizona. He is affiliated with Saint Alphonsus Regional Medical Center, Saint Alphonsus Medical Center - Nampa, and West Valley Medical Center.
Education & Training
University of Arizona College of Medicine-TucsonFellowship, Nephrology, 1999 - 2001- University of Arizona College of Medicine-TucsonResidency, Internal Medicine, 1996 - 1999
- University of Arizona College of MedicineClass of 1996
Certifications & Licensure
ID State Medical License 2005 - 2026
AZ State Medical License 2000 - 2010- American Board of Internal Medicine Nephrology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Aprima EHR, Aprima Medical Software, Inc., 2012-2013
Clinical Trials
- A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD) Start of enrollment: 2012 Jul 01
- A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL Start of enrollment: 2017 Mar 02
Publications & Presentations
PubMed
- Tenapanor improves long-term control of high phosphate concentrations in the blood in patients receiving maintenance dialysis: a plain language summary of the NORMALIZ...Arnold Silva, Susan Edelstein, Yang Yang, David Rosenbaum, Lori Battelli
Current Medical Research and Opinion. 2024-08-01 - 1 citationsTenapanor as Therapy for Hyperphosphatemia in Maintenance Dialysis Patients: Results from the OPTIMIZE Study.Stuart M Sprague, Daniel E Weiner, David P Tietjen, Pablo E Pergola, Steven Fishbane
Kidney360. 2024-05-01 - 21 citationsEfficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial.Katherine R Tuttle, Sibylle J Hauske, Maria Eugenia Canziani, Maria Luiza Caramori, David Cherney
Lancet. 2024-01-27
Press Mentions
Reata Announces Presentation of Four Clinical Abstracts at the American Society of Nephrology Kidney Week 2018May 2nd, 2019
